

MTN 015 HIV-1 Seroconverter Study

**Seroconverters from Protocol 025
Study Enrollment by Site
Data as of 09JUN2020**

| | <i>All Sites</i> | <i>Malawi: Blantyre</i> | <i>Malawi: Lilongwe</i> | <i>South Africa: Bothas Hill</i> | <i>South Africa: Emavundleni Centre</i> | <i>South Africa: Isipingo</i> | <i>South Africa: RK Khan</i> | <i>South Africa: Verulam</i> |
|---|------------------|-----------------------------|-----------------------------|--------------------------------------|---|-----------------------------------|----------------------------------|----------------------------------|
| DAIDS Site ID | NA | 30301 | 12001 | 31445 | 30346 | 31635 | 30302 | 31663 |
| Site Activation Date | NA | 09JAN09 | 01AUG08 | 11JUN10 | 19DEC13 | 11JUN10 | 25MAR09 | 11JUN10 |
| Date of First Enrollment | 10APR2017 | 09MAR2018 | 03APR2018 | - | 23MAR2018 | - | 10APR2017 | 23JUN2017 |
| Time from Seroconversion to Enrollment | | | | | | | | |
| Within 30 days | (40.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 31 to 90 days | (40.0%) | (100.0%) | (0.0%) | - | (50.0%) | - | (50.0%) | (100.0%) |
| 91 to 180 days | (20.0%) | (0.0%) | (100.0%) | - | (50.0%) | - | (50.0%) | (0.0%) |
| 181 to 360 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 361 to 540 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 541 to 720 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 721 to 900 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 901 to 1080 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| > 1080 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |

MTN 015 HIV-1 Seroconverter Study

**Seroconverters from Protocol 025
Study Enrollment by Site
Data as of 09JUN2020**

| | <i>South Africa: WRHI</i> | <i>South Africa: eThekweni</i> | <i>Uganda: MU-JHU</i> | <i>Zimbabwe: Seke South</i> | <i>Zimbabwe: Spilhaus</i> | <i>Zimbabwe: Zengeza</i> |
|--|-------------------------------|------------------------------------|---------------------------|---------------------------------|-------------------------------|------------------------------|
| DAIDS Site ID | 31639 | 31422 | 30293 | 30294 | 30314 | 30320 |
| Site Activation Date | 14MAR11 | 05NOV10 | 09NOV10 | 17FEB09 | 17FEB09 | 05MAR10 |
| Date of First Enrollment | 02AUG2017 | 03OCT2017 | - | - | 28MAR2018 | 18MAY2017 |
| Time from Seroconversion to Enrollment | | | | | | |
| Within 30 days | (33.3%) | (100.0%) | - | - | (0.0%) | (83.3%) |
| 31 to 90 days | (66.7%) | (0.0%) | - | - | (50.0%) | (16.7%) |
| 91 to 180 days | (0.0%) | (0.0%) | - | - | (50.0%) | (0.0%) |
| 181 to 360 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |
| 361 to 540 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |
| 541 to 720 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |
| 721 to 900 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |
| 901 to 1080 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |
| > 1080 days | (0.0%) | (0.0%) | - | - | (0.0%) | (0.0%) |

MTN 015 HIV-1 Seroconverter Study

**Seroconverters from Protocol 025
Study Enrollment by Site
Data as of 09JUN2020**

| | <i>All Sites</i> | <i>Malawi: Blantyre</i> | <i>Malawi: Lilongwe</i> | <i>South Africa: Bothas Hill</i> | <i>South Africa: Emavundleni Centre</i> | <i>South Africa: Isipingo</i> | <i>South Africa: RK Khan</i> | <i>South Africa: Verulam</i> |
|--|------------------|-----------------------------|-----------------------------|--------------------------------------|---|-----------------------------------|----------------------------------|----------------------------------|
| Participants who Initiated ART Prior to Enrollment | | | | | | | | |
| Time from ART Initiation to Enrollment | | | | | | | | |
| Within 30 days | (55.6%) | (100.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 31 to 90 days | (33.3%) | (0.0%) | (0.0%) | - | (100.0%) | - | (100.0%) | (100.0%) |
| 91 to 180 days | (11.1%) | (0.0%) | (100.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 181 to 360 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 361 to 540 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 541 to 720 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 721 to 900 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| 901 to 1080 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |
| > 1080 days | (0.0%) | (0.0%) | (0.0%) | - | (0.0%) | - | (0.0%) | (0.0%) |

| | <i>South Africa: WRHI</i> | <i>South Africa: eThekweni</i> | <i>Uganda: MU-JHU</i> | <i>Zimbabwe: Seke South</i> | <i>Zimbabwe: Spilhaus</i> | <i>Zimbabwe: Zengeza</i> |
|--|-------------------------------|------------------------------------|---------------------------|---------------------------------|-------------------------------|------------------------------|
| Participants who Initiated ART Prior to Enrollment | | | | | | |
| Time from ART Initiation to Enrollment | | | | | | |
| Within 30 days | - | - | - | - | - | (100.0%) |
| 31 to 90 days | - | - | - | - | - | (0.0%) |
| 91 to 180 days | - | - | - | - | - | (0.0%) |
| 181 to 360 days | - | - | - | - | - | (0.0%) |
| 361 to 540 days | - | - | - | - | - | (0.0%) |
| 541 to 720 days | - | - | - | - | - | (0.0%) |
| 721 to 900 days | - | - | - | - | - | (0.0%) |
| 901 to 1080 days | - | - | - | - | - | (0.0%) |
| > 1080 days | - | - | - | - | - | (0.0%) |